Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Radiology, Nuclear Medicine & Medical Imaging, preclinical positron emission tomography (mu PET);, cerebral adenosine A(2A) receptor, F-18-SCH442416 analogs, kinetic analysis, rat brain, BASAL GANGLIA, TEST-RETEST, BINDING, VIOLATIONS, LIGAND, 18F-SCH442416 analogs, cerebral adenosine A2A receptor, preclinical positron emission tomography (μPET), Adenosine A2 Receptor Antagonists, Animals, Brain, Fluorine Radioisotopes, Male, Metabolic Clearance Rate, Molecular Imaging, Organ Specificity, Positron-Emission Tomography, Pyrazoles, Pyrimidines, Radiopharmaceuticals, Rats, Rats, Wistar, Receptor, Adenosine A2A, Reproducibility of Results, Sensitivity and Specificity, Tissue Distribution, 1103 Clinical Sciences, Nuclear Medicine & Medical Imaging, 3202 Clinical sciences

Abstract:

Cerebral adenosine A2A receptors (A2ARs) are attractive therapeutic targets for neuropsychiatric disorders. (18)F-Fluoroethyl and (18)F-fluoropropyl analogs of SCH442416 ((18)F-FESCH and (18)F-FPSCH) were developed as A2AR specific PET ligands. Aim is to determine an appropriate compartmental model for tracer kinetics, evaluate a reference tissue approach and select the most suitable PET ligand.